Opko Health Inc (OPK) 13.80 $OPK
52.0% Return Seen to Date on SmarTrend Opko Health Call (OPK)
Comtex SmarTrend(R) - Fri Feb 13, 4:36PM CST
SmarTrend identified an Uptrend for Opko Health (NYSE:OPK) on December 15th, 2014 at $9.08. In approximately 2 months, Opko Health has returned 51.98% as of today's recent price of $13.80.
OPK: 13.80 (-0.28)
OPKO Health to Present at the 2015 RBC Capital Markets' Healthcare Conference
Business Wire - Fri Feb 13, 11:13AM CST
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the 2015 RBC Capital Markets' Healthcare Conference on Wednesday, February 25, 2015 at 2:35 PM (ET).
OPK: 13.80 (-0.28)
Opko Health (OPK) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:02AM CST
Trade-Ideas LLC identified Opko Health (OPK) as a weak on high relative volume candidate
OPK: 13.80 (-0.28)
Opko Health: Potential At A Good Cost
Stkmrkt - at Seeking Alpha - Wed Feb 11, 1:58PM CST
OPK: 13.80 (-0.28)
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 13.80 (-0.28), MDW: 0.70 (+0.02)
Opko Health (OPK) in Focus: Stock Jumps 5.3% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Tue Feb 10, 8:18AM CST
Opko Health, Inc. (OPK) was a big mover last session, as the company saw its shares rise over 5% on the day.
ABMD: 60.39 (+0.46), OPK: 13.80 (-0.28)
Look for Shares of Opko Health to Potentially Pullback after Yesterday's 5.19% Rise
Comtex SmarTrend(R) - Mon Feb 09, 5:06PM CST
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $13.51 to a high of $14.59. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $13.99 on volume of 9.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 13.80 (-0.28)
Shares of OPK Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 10:55AM CST
SmarTrend identified an Uptrend for Opko Health (NYSE:OPK) on December 15th, 2014 at $9.08. In approximately 2 months, Opko Health has returned 53.08% as of today's recent price of $13.90.
OPK: 13.80 (-0.28)
Departure of prominent Teva board member stokes speculative buying
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 2:23PM CST
OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
Investments Gamma. Frost Trust of Opko Health, Inc. (OPK)-NY bought Shares of OPK
M2 - Thu Feb 05, 7:23AM CST
Reported by InsiderCow.com at 2015-02-04 09:13:51 ET
OPK: 13.80 (-0.28)
InsiderInsights.com Daily Round Up 2/4/15: BZH, MLNK, CDNA, FDBC
InsiderInsights - at Seeking Alpha - Thu Feb 05, 6:39AM CST
LBTYK: 50.78 (+2.40), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), BBY: 39.11 (-0.08), MLNK: 3.78 (+0.04), BZH: 17.13 (-0.04), QVCA: 29.47 (+0.42), BA: 149.73 (+1.64), OCUL: 31.25 (-0.01), LMCA: 37.97 (+0.06), OPK: 13.80 (-0.28), CDNA: 6.30 (-0.14), ENTL: 21.99 (+0.56), MSFT: 43.87 (+0.78), SCHW: 29.13 (-0.83)
Why Opko Health Inc. Shares Launched 21% Higher in January
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 7:03AM CST
What: Shares of Opko Health , a healthcare company focused on developing pharmaceutical products and diagnostic solutions for a range of illnesses, launched 21% higher in January per S&P Capital IQ primarily as a continuation of investor...
OPK: 13.80 (-0.28), PFE: 34.64 (-0.23)
Opko Health (OPK) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Tue Feb 03, 10:21AM CST
Trade-Ideas LLC identified Opko Health (OPK) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
OPK: 13.80 (-0.28)
OPKO submits investigational NDA to begin Phase 2a Trial for Factor VIIa-CTP for treating hemophilia
M2 - Mon Feb 02, 6:05AM CST
Biopharmaceutical company OPKO Health (NYSE:OPK) stated on Friday that it plans to conduct a Phase 2a study of Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
OPK: 13.80 (-0.28)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 61.83 (+0.67), CSWC: 46.54 (+1.20), FCS: 16.37 (-0.07), MLNK: 3.78 (+0.04), ADBE: 76.51 (+1.92), VSAR: 18.04 (-0.55), LCI: 57.78 (-0.91), WIW: 11.29 (unch), QRVO: 70.03 (+3.83), PSEM: 14.82 (-0.12), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), BGG: 20.18 (+0.09), RWC: 5.82 (+0.06), PE: 17.28 (+0.80), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21), FPRX: 24.63 (+0.63), INFN: 17.56 (-0.10)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
52.0% Return Seen to Date on SmarTrend Opko Health Call (OPK)
Comtex SmarTrend(R) - Fri Feb 13, 4:36PM CST
SmarTrend identified an Uptrend for Opko Health (NYSE:OPK) on December 15th, 2014 at $9.08. In approximately 2 months, Opko Health has returned 51.98% as of today's recent price of $13.80.
OPK: 13.80 (-0.28)
OPKO Health to Present at the 2015 RBC Capital Markets' Healthcare Conference
Business Wire - Fri Feb 13, 11:13AM CST
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the 2015 RBC Capital Markets' Healthcare Conference on Wednesday, February 25, 2015 at 2:35 PM (ET).
OPK: 13.80 (-0.28)
Opko Health (OPK) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:02AM CST
Trade-Ideas LLC identified Opko Health (OPK) as a weak on high relative volume candidate
OPK: 13.80 (-0.28)
Opko Health: Potential At A Good Cost
Stkmrkt - at Seeking Alpha - Wed Feb 11, 1:58PM CST
OPK: 13.80 (-0.28)
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 13.80 (-0.28), MDW: 0.70 (+0.02)
Opko Health (OPK) in Focus: Stock Jumps 5.3% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Tue Feb 10, 8:18AM CST
Opko Health, Inc. (OPK) was a big mover last session, as the company saw its shares rise over 5% on the day.
ABMD: 60.39 (+0.46), OPK: 13.80 (-0.28)
Look for Shares of Opko Health to Potentially Pullback after Yesterday's 5.19% Rise
Comtex SmarTrend(R) - Mon Feb 09, 5:06PM CST
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $13.51 to a high of $14.59. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $13.99 on volume of 9.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OPK: 13.80 (-0.28)
Shares of OPK Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 10:55AM CST
SmarTrend identified an Uptrend for Opko Health (NYSE:OPK) on December 15th, 2014 at $9.08. In approximately 2 months, Opko Health has returned 53.08% as of today's recent price of $13.90.
OPK: 13.80 (-0.28)
Departure of prominent Teva board member stokes speculative buying
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 2:23PM CST
OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
Investments Gamma. Frost Trust of Opko Health, Inc. (OPK)-NY bought Shares of OPK
M2 - Thu Feb 05, 7:23AM CST
Reported by InsiderCow.com at 2015-02-04 09:13:51 ET
OPK: 13.80 (-0.28)
InsiderInsights.com Daily Round Up 2/4/15: BZH, MLNK, CDNA, FDBC
InsiderInsights - at Seeking Alpha - Thu Feb 05, 6:39AM CST
LBTYK: 50.78 (+2.40), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), BBY: 39.11 (-0.08), MLNK: 3.78 (+0.04), BZH: 17.13 (-0.04), QVCA: 29.47 (+0.42), BA: 149.73 (+1.64), OCUL: 31.25 (-0.01), LMCA: 37.97 (+0.06), OPK: 13.80 (-0.28), CDNA: 6.30 (-0.14), ENTL: 21.99 (+0.56), MSFT: 43.87 (+0.78), SCHW: 29.13 (-0.83)
Why Opko Health Inc. Shares Launched 21% Higher in January
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 7:03AM CST
What: Shares of Opko Health , a healthcare company focused on developing pharmaceutical products and diagnostic solutions for a range of illnesses, launched 21% higher in January per S&P Capital IQ primarily as a continuation of investor...
OPK: 13.80 (-0.28), PFE: 34.64 (-0.23)
Opko Health (OPK) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Tue Feb 03, 10:21AM CST
Trade-Ideas LLC identified Opko Health (OPK) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
OPK: 13.80 (-0.28)
OPKO submits investigational NDA to begin Phase 2a Trial for Factor VIIa-CTP for treating hemophilia
M2 - Mon Feb 02, 6:05AM CST
Biopharmaceutical company OPKO Health (NYSE:OPK) stated on Friday that it plans to conduct a Phase 2a study of Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
OPK: 13.80 (-0.28)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST
STX: 61.83 (+0.67), CSWC: 46.54 (+1.20), FCS: 16.37 (-0.07), MLNK: 3.78 (+0.04), ADBE: 76.51 (+1.92), VSAR: 18.04 (-0.55), LCI: 57.78 (-0.91), WIW: 11.29 (unch), QRVO: 70.03 (+3.83), PSEM: 14.82 (-0.12), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), BGG: 20.18 (+0.09), RWC: 5.82 (+0.06), PE: 17.28 (+0.80), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21), FPRX: 24.63 (+0.63), INFN: 17.56 (-0.10)
Opko files IND for study of long-acting clotting factor
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:31AM CST
BIIB: 391.66 (-0.45), ALNY: 95.54 (+1.67), OPK: 13.80 (-0.28), BAX: 70.39 (+0.31), SGMO: 15.40 (+0.14)
